Insilico Medicine

Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for…

Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development,…

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel…

Multi-year collaboration will use artificial intelligence (AI) and deep learning to accelerate the invention of new, more sustainable products and…

Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel…

Insilico Medicine announces the first deployment of its flagship generative chemistry AI platform for de novo molecular design, Chemistry42 on Merck…

Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical…

A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel…

Nanome, Inc., a virtual reality (VR) startup whose signature product is a computational chemistry software platform, has co-authored a paper…

Insilico Medicine announced that MIT Technology Review selected AI-discovered molecules as a breakthrough of the year with the availability…